← ANALYST RATINGS · TIPRANKS
Align Tech (ALGN): analyst forecast and price target
Analyst consensus
Moderate Buy7 Buy5 Hold1 Sell
Ratings of 13 analysts in the last 3 months12-month forecast
Based on 13 price targets given in the last 3 months, the average target is $197, the highest $240, the lowest $155. The average is +33.6% from the last price of $147.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Jeff Johnson★★★★★★★★★★#1125 · hits 51% · avg +10.4% | Robert W. Baird | $218 → $162−25.7% | Hold | +10.0% | Downgrade | 15.10.26on TipRanks 05:30 | +3.1%next day −0.3% | ↗ |
| Michael Cherny★★★★★★★★★★#2074 · hits 57% · avg +5.7% | Leerink Partners | $235 → $215−8.5% | Buy | +46.0% | Reiterated | 14.10.26on TipRanks 08:55 | +1.7%next day +3.1% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $158 → $155−1.9% | Buy | +5.2% | Reiterated | 13.10.26on TipRanks 11:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $153 → $150−2.0% | Hold | +1.8% | Downgrade | 13.10.26on TipRanks 11:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $157 → $154−1.9% | Buy | +4.5% | Reiterated | 13.10.26on TipRanks 11:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $149 → $147−1.3% | Hold | −0.2% | Reiterated | 13.10.26on TipRanks 11:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $157 → $154−1.9% | Buy | +4.5% | Reiterated | 13.10.26on TipRanks 11:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $158 → $156−1.3% | Buy | +5.9% | Reiterated | 13.10.26on TipRanks 11:05 | — | |
| Jonathan Block★★★★★★★★★★#2320 · hits 50% · avg +5.3% | Stifel Nicolaus | $210 → $175−16.7% | Buy | +18.8% | Reiterated | 09.10.26on TipRanks 07:20 | +0.6%next day −1.5% · 5 days +5.2% | ↗ |
| Elizabeth Anderson CFA★★★★★★★★★★#2664 · hits 55% · avg +4.4% | Evercore ISI | $220 → $155−29.5% | Hold | +5.2% | Downgrade | 05.10.26on TipRanks 05:35 | −2.8%next day 0.0% · 5 days −0.6% | ↗ |
| Jason Bednar★★★★★★★★★★#11450 · hits 46% · avg −2.5% | Piper Sandler | $235 | Buy | +59.5% | Reiterated | 16.09.26on TipRanks 07:15 | +2.8%next day −1.6% · 5 days −3.6% | ↗ |
| Brandon Vazquez★★★★★★★★★★#11688 · hits 42% · avg −5.1% | William Blair | — | Buy | — | Reiterated | 03.09.26on TipRanks 10:55 | −0.6%next day −0.4% · 5 days −4.5% | ↗ |
| Vik Chopra★★★★★★★★★★#6076 · hits 45% · avg +1.9% | BMO Capital | $209 | Buy | +41.9% | Reiterated | 12.08.26on TipRanks Aug 13 11:15 | +0.4%next day +0.6% · 5 days −5.9% | ↗ |
| Glen Santangelo★★★★★★★★★★#2956 · hits 52% · avg +4.5% | Barclays | $200 | Buy | +35.8% | Reiterated | 05.08.26on TipRanks 04:13 | +1.1%next day −3.1% · 5 days −0.8% | ↗ |
| Daniel Grosslight★★★★★★★★★★#4007 · hits 47% · avg +3.6% | Citi | $240 | Buy | +62.9% | Reiterated | 03.08.26on TipRanks 06:55 | +0.8%next day −1.6% · 5 days −0.2% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | — | Sell | — | Reiterated | 30.07.26on TipRanks 13:13 | −5.4%next day −3.2% · 5 days −6.1% | ↗ |
| Erin Wright★★★★★★★★★★#354 · hits 64% · avg +15.1% | Morgan Stanley | $188 | Hold | +27.6% | Reiterated | 30.07.26on TipRanks 08:20 | −5.4%next day −3.2% · 5 days −6.1% | ↗ |
| David Saxon★★★★★★★★★★#6662 · hits 38% · avg +0.8% | Needham | — | Hold | — | Reiterated | 30.07.26on TipRanks 07:37 | −5.4%next day −3.2% · 5 days −6.1% | ↗ |
| Kevin Caliendo★★★★★★★★★★#2646 · hits 56% · avg +5.6% | UBS | $186 → $189+1.6% | Hold | +28.3% | Reiterated | 23.07.26on TipRanks Jul 24 07:31 | −1.2%next day −0.8% · 5 days +2.6% | ↗ |
| Steven Valiquette★★★★★★★★★★#8240 · hits 53% · avg 0.0% | Mizuho Securities | $215 → $220+2.3% | Buy | +49.3% | Reiterated | 30.04.26on TipRanks May 1 08:20 | −2.3%next day +1.4% · 5 days −6.1% | ↗ |
| Sidharth Sahoo★★★★★★★★★★#9090 · hits 43% · avg −0.9% | HSBC | $150 → $200+33.3% | Buy | +35.8% | Upgrade | 09.02.26on TipRanks 04:30 | +2.1%next day +2.2% · 5 days −1.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Align Tech
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $211 at a price of $145 (+45.4%); now: $197 at $147 (+33.6%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 18 | 21 | 19 | 17 | 13 | 8 |
| Hold | 5 | 5 | 6 | 4 | 4 | 2 |
| Sell | 2 | 2 | 2 | 1 | 1 | 0 |
Earnings and sales forecast
Next report: 28.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.78 (from $2.67 to $2.88). Last quarter: $2.64.
Sales
Next quarter’s sales estimate — $1.0B (from $965M to $1.0B). Last quarter: $1.1B.
Best top-analyst consensus in the sector · Healthcare
About Align Tech
- CEO: Joseph Hogan
- Employees: 20,435
- 410 North Scottsdale Road, Tempe, AZ, 85288, US
- www.aligntech.com
Align Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry. The company's operations are divided into two main business units: "Clear Aligner" and "Scanners and Services." The Clear Aligner segment offers a variety of solutions. Its comprehensive products include the full Invisalign treatment for teenage patients, designed to address complex orthodontic needs such as mandibular advancement, patient compliance tracking, and managing tooth eruption. It also features specialized Invisalign First Phase I and Phase 2 packages for younger children, typically aged seven to ten, who have mixed dentition (a combination of primary and permanent teeth). Beyond these, the segment provides non-comprehensive aligner options like Invisalign moderate, lite, express, and Invisalign Go. Additional non-case products include retention devices, fees for Invisalign training, and sales of ancillary items such as cleaning materials and adjustment tools used by dental practitioners during treatment. The Scanners and Services segment centers around the iTero scanner, a unified hardware platform offering various software applications for both restorative and orthodontic procedures. It supplies specialized restorative software to general dentists, prosthodontists, periodontists, and oral surgeons, as well as distinct software for orthodontists to manage digital patient records, perform diagnoses, and facilitate the fabrication of printed models and retainers. This segment also provides computer-aided design and manufacturing (CAD/CAM) services, along with supplementary products like disposable covers for the scanner wand and iTero models and dies. Furthermore, it includes
Data from the stock’s TipRanks forecast page, read 13 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗